SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from 11 clinical studies with its molecular diagnostic tests will be featured at the 2014 American Society of Clinical Oncology annual meeting to be held May 30-June 3, 2014 in Chicago, Ill. Abstracts of the Company's presentations are available at: abstracts.asco.org.
The molecular diagnostic tests being highlighted at ASCO address four key areas of focus for Myriad including hereditary cancer, melanoma, companion diagnostics and prostate cancer. There will be presentations on six new key studies on the Myriad myRisk™ Hereditary Cancer test, including two podium presentations; two presentations on the Myriad myPath™ Melanoma test, including the first pivotal clinical validation study; and the presentation of new clinical data on the HRD companion diagnostic in patients with metastatic triple negative breast cancer.
"Myriad is committed to advancing all aspects of cancer care – risk assessment, diagnosis, prognosis and treatment selection – and has a robust portfolio and pipeline of molecular and companion diagnostics," said Mark Capone, president of Myriad Genetics Laboratories. "We believe much more can be done through diagnostics to improve patient care and lower health care costs. Through our strong internal and external research programs, Myriad is leading the discovery, development and commercialization of the next generation of diagnostic tests and services."
The list of key Myriad presentations follows.
|Myriad myRisk Hereditary Cancer Testing|
|Title:||A study of ovarian cancer patients tested with a 25-gene panel of hereditary cancer genes.|
|Date:||Monday, June 2, 8:48 a.m. - 9:00 a.m. (Podium Presentation; Location S100a)|
|Title:||Multigene panel testing in patients suspected to have Lynch syndrome.|
|Date:||Monday, June 2, 8:00 a.m. - 8:12 a.m. (Podium Presentation; Location S100a)|
|Title:||Analysis of patients with two hereditary cancers (breast/ovarian or colon/endometrial) who met NCCN genetic testing criteria after their first cancer.|
|Date:||Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1542)|
|Title:||Impact of 25-gene panel testing and integrated risk management tool on medical management in hereditary cancer syndrome evaluation.|
|Date:||Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1553)|
|Title:||The clinical experience: Hereditary cancer testing by a 25-gene panel.|
|Date:||Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1548)|
|Title:||Evaluation of breast cancer incidence in Lynch syndrome patients by MMR gene.|
|Date:||Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1541)|
|Myriad myPath Melanoma|
|Title:||Development and validation of a gene expression signature to distinguish malignant melanoma from benign nevi.|
|Date:||Monday, June 2, 8:00 a.m. - 12:00 p.m.; Discussion 11:30 a.m. – 12:45 p.m. (Highlighted Poster 9021)|
|Title:||The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists.|
|Date:||Saturday, May 31, 8:00 a.m. - 11:45 a.m. (Poster TPS9111)|
|HRD (Companion Diagnostic)|
| Title: ||Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple negative breast cancer (mTNBC): Correlative studies from TBCRC009.|
|Date:||Tuesday, June 3, 9:45 a.m. - 12:45 p.m. (Podium Presentation; Location E Hall D1)|
| Title: ||TBCRC030: A randomized phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple negative breast cancer (TNBC): Evaluating the Homologous Recombination Deficiency (HRD) Biomarker|
|Date:||Monday, June 2, 8:00 a.m. - 11:45 a.m. (Poster TPS1445)|
|Title:||Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort|
|Date:||Monday, June 2, 1:15 p.m. - 5:00 p.m. (Poster 5059)|
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, and Myriad myRisk are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the dates, times and presentation of clinical study data at the 2014 ASCO Annual Meeting; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
Source:Myriad Genetics, Inc.